ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ABVC ABVC BioPharma, Inc.

Market Closed 11-15 16:00:00 EST

0.5000

-0.0510

-9.26%

盘后0.5051

+0.0051+1.02%

19:02 EST

High0.5800	Low0.5000	Vol176.35K
Open0.5800	D1 Closing0.5510	Amplitude14.52%
Mkt Cap6.49M	Tradable Cap5.06M	Total Shares12.98M
T/O92.43K	T/O Rate1.74%	Tradable Shares10.13M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ABVC","market":"US","secType":"STK","nameCN":"ABVC BioPharma, Inc.","latestPrice":0.500001,"timestamp":1731704400000,"preClose":0.551,"halted":0,"volume":176345,"hourTrading":{"tag":"盘后","latestPrice":0.5051,"preClose":0.500001,"latestTime":"19:02 EST","volume":911,"amount":460.151,"timestamp":1731715364316},"delay":0,"floatShares":10127000,"shares":12975492,"eps":-1.432425,"marketStatus":"Market Closed","change":-0.050999,"latestTime":"11-15 16:00:00 EST","open":0.58,"high":0.58,"low":0.5,"amount":92433.072792,"amplitude":0.145191,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.432425,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1731920400000},"marketStatusCode":7,"adr":0,"listingDate":1627963200000,"exchange":"NASDAQ","adjPreClose":0.551,"preHourTrading":{"tag":"盘前","latestPrice":0.5509,"preClose":0.551,"latestTime":"09:26 EST","volume":8022,"amount":4491.611657,"timestamp":1731680760058},"postHourTrading":{"tag":"盘后","latestPrice":0.5051,"preClose":0.500001,"latestTime":"19:02 EST","volume":911,"amount":460.151,"timestamp":1731715364316},"volumeRatio":1.5505256222421635},"requestUrl":"/m/hq/s/ABVC/wiki","defaultTab":"wiki","newsList":[{"id":"2483980529","title":"ABVC BioPharma Q3 EPS $(0.02) Up From $(0.82) YoY, Sales $389.28K Up From $15.88K YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483980529","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483980529?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:01","pubTimestamp":1731592913,"startTime":"0","endTime":"0","summary":"ABVC BioPharma Q3 EPS $(0.02) Up From $(0.82) YoY, Sales $389.28K Up From $15.88K YoY","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41973064/abvc-biopharma-q3-eps-0-02-up-from-0-82-yoy-sales-389-28k-up-from-15-88k-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"ABVC BioPharma Q3 EPS $(0.02) Up From $(0.82) YoY, Sales $389.28K Up From $15.88K YoY","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC"],"gpt_icon":0},{"id":"2483805246","title":"ABVC Biopharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2483805246","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483805246?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:00","pubTimestamp":1731592804,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nTUA4GTDXK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2483068058","title":"ABVC BioPharma, Inc. Reports Q3 2024 Financial Results and Operational Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2483068058","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483068058?lang=en_us&edition=fundamental","pubTime":"2024-11-14 22:00","pubTimestamp":1731592800,"startTime":"0","endTime":"0","summary":"ABVC BioPharma Achieved its First Operational Profit, with a 102% Improvement over the Third Quarter of Last Year.Incremental Payments Received based on Executed Global Licensing Agreements that could provide up to $292 million in income. Received Cash Milestone Incomes of $496,000 for the nine months ended September 30, 2024. Impressive Revenue Growth: ABVC reported a significant increase in revenue, reaching $389,276 in Q3 2024, from $15,884 in the third quarter of 2023. This growth reflects the growing demand for our CNS and oncology R&D services and highlights the positive potential of our strategic partnerships.Continued Improvement in Earnings: The Company’s net loss for Q3 2024 decreased substantially to $134,272 from $3.37 million in Q3 2023. This positive net loss reduction trend results from disciplined financial management and focused R&D investments, underscoring our commitment to building a sustainable growth pathway.In Q3, ABVC's continued collaboration with OncoX expande","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/veBmG9tA7KV3I5j9OOvp7A--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c70a8cb5ca8fe5ff7c3b7770910e7240","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/veBmG9tA7KV3I5j9OOvp7A--~B/aD0zODY7dz00NDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/c70a8cb5ca8fe5ff7c3b7770910e7240"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/abvc-biopharma-inc-reports-q3-140000951.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","BK4213","ABVC","TGA"],"gpt_icon":1},{"id":"2483345863","title":"Aytu BioPharma Reports Fiscal 2025 First Quarter Operational and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483345863","media":"ACCESSWIRE","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483345863?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:05","pubTimestamp":1731531900,"startTime":"0","endTime":"0","summary":"Organizational changes and operating optimization plan implemented to further streamline operations, reduce expenses, and accelerate path to consistent cash flow. DENVER, CO / ACCESSWIRE / November 13, 2024 / Aytu BioPharma, Inc.  , a pharmaceutical company focused on commercializing novel therapeutics, today announced operational and financial results for the fiscal 2025 first quarter.\"The initiatives we undertook two years ago to reposition Aytu as a growing specialty pharmaceutical company focused on commercializing novel prescription therapeutics were done with an aim towards driving consistent operating cash flow. The results of the first quarter continue to showcase the positive impact from these initiatives as we reported our sixth consecutive quarter of positive adjusted EBITDA and posted positive net income for the first time in the Company's history,\" commented Josh Disbrow, Chief Executive Officer of Aytu. \"Looking forward, we expect to further accelerate our profitability g","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/aytu-biopharma-reports-fiscal-2025-210500624.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVC","BK4139","AYTU","ADHD","BK4007"],"gpt_icon":0},{"id":"2483833259","title":"This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho","url":"https://stock-news.laohu8.com/highlight/detail?id=2483833259","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483833259?lang=en_us&edition=fundamental","pubTime":"2024-11-14 00:03","pubTimestamp":1731513780,"startTime":"0","endTime":"0","summary":"It's been 30 years since a novel mechanism of action was approved for the debilitating illness. Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for major depressive disorder, or MDD, later this year.Watertown, Mass.-based Neumora , a clinical-stage biotech that went public in September of 2023, specializes in treatments for central nervous system diseases. Its pipeline includes treatments for bipolar depression, agitation in Alzheimer's disease, schizophrenia and Parkinson's disease.The company's lead product candidate, navacaprant, aims to treat MDD, the leading cause of disability worldwide, according to research conducted by L.E.K. Consulting.An estimated 280 million people around the world suffer from MDD, 21 million of whom are resident in the U.S. It's been 30 years since a novel mechanism of action was approved, creating a high unmet nee","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ABVC","BK4207","BK4139","MFG","BK4007","NMRA"],"gpt_icon":0},{"id":"2483371358","title":"Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2483371358","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483371358?lang=en_us&edition=fundamental","pubTime":"2024-11-13 23:50","pubTimestamp":1731513000,"startTime":"0","endTime":"0","summary":"Xenon Pharmaceuticals Inc.XENE reported a loss of 81 cents per share for the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 82 cents. The company had incurred a loss of 73 cents per share in the year-ago quarter.In the reported quarter, Xenon did not generate any revenues. Due to the absence of a marketed product, the company only recognizes periodic collaboration revenues in its top line from its ongoing partnership with Neurocrine Biosciences NBIX for XEN901, now known as NBI-921352. The company did not recognize any revenues in the year-ago quarter as well.NBI-921352 is a selective Nav1.6 sodium channel inhibitor. Neurocrine is currently evaluating NBI-921352 in a phase II study to treat patients aged 2-21 years with SCN8A developmental and epileptic encephalopathy. Per the terms of the agreement with NBIX, Xenon is eligible to receive certain clinical, regulatory and commercial milestone-based payments, as well as royalties on future sales.Xenon, in ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/kHYuj_GDhroF7BEQsCcsVA--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/4658663242c3a61dee3fef55a1bf4887"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xenon-q3-loss-narrower-expected-155000607.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU2065171402.SGD","BIIB","LU2065169927.USD","BK4588","ALLO","BK4532","BK4505","BK4585","LU2065171311.SGD","IE00B19Z9P08.USD","LU0320765992.SGD","LU0823416689.USD","BK4139","IE00B19Z9Z06.USD","LU2324357040.USD","NBIX","XENE","LU0889565916.HKD","LU2065170008.USD","ABVC","LU0109394709.USD","IE00B894F039.SGD","LU0234570918.USD","BK4533"],"gpt_icon":0},{"id":"2483842004","title":"Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2483842004","media":"Business Wire","labels":["Product Release"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483842004?lang=en_us&edition=fundamental","pubTime":"2024-11-13 20:30","pubTimestamp":1731501000,"startTime":"0","endTime":"0","summary":"- PARADIGM  program comprises two 12-week randomized, placebo-controlled studies  and a long-term extension study  -. - APPROACH : A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans with Major Depressive Disorder has been initiated and will enroll 220 patients at 36 clinical sites across the U.S. and Europe; topline results expected in 2026 -. \"Just three years after filing an Investigational New Drug application for CYB003, the initiation of our Phase 3 program is a truly significant and gratifying milestone,\" said Doug Drysdale, Chief Executive Officer of Cybin. \"Following a highly collaborative and thorough design and review process with the U.S. Food and Drug Administration, we believe that PARADIGM incorporates appropriate protocols that proactively address some of the challenges encountered by peers developing molecules with similar mechanisms of action by  recruiting from the larger MDD populat","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/8E1KZfTz0sWx.9LKB9rfkg--~B/aD0yNTM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/91e3f38405339535944d9c4c033a34fd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/8E1KZfTz0sWx.9LKB9rfkg--~B/aD0yNTM7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/91e3f38405339535944d9c4c033a34fd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cybin-initiates-paradigm-multinational-pivotal-123000583.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVC","BK4007","BK4139","CYBN","BK4168"],"gpt_icon":0},{"id":"2483046332","title":"BlinkLab joins ‘landmark’ Monash University autism/ADHD project","url":"https://stock-news.laohu8.com/highlight/detail?id=2483046332","media":"Stockheads","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483046332?lang=en_us&edition=fundamental","pubTime":"2024-11-13 13:54","pubTimestamp":1731477273,"startTime":"0","endTime":"0","summary":"BlinkLab will participate in MAGNET project run by Monash University. Enrolment is planned for 1000 families with children diagnosed with only autism, only ADHD, or both. Project aims to identify novel autism and ADHD subtypes using comprehensive data collection","market":"us","thumbnail":"https://stockhead.com.au/wp-content/uploads/2024/11/GettyImages-506902994-1200x675-1-640x360.jpg","type":0,"news_type":0,"thumbnails":["https://stockhead.com.au/wp-content/uploads/2024/11/GettyImages-506902994-1200x675-1-640x360.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stockhead.com.au/health/blinklab-joins-landmark-monash-university-autism-adhd-project/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockheads_stock","symbols":["BK4139","BK4585","BK4213","ADHD","ABVC","APA","BK4588"],"gpt_icon":0},{"id":"2483099928","title":"BlinkLab Joins Monash Project to Revolutionize Autism and ADHD Diagnosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2483099928","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483099928?lang=en_us&edition=fundamental","pubTime":"2024-11-13 08:51","pubTimestamp":1731459076,"startTime":"0","endTime":"0","summary":"Blinklab Limited (AU:BB1) has released an update. BlinkLab Limited is set to participate in the MAGNET project by Monash University, which aims to ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/blinklab-joins-monash-project-to-revolutionize-autism-and-adhd-diagnosis?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/blinklab-joins-monash-project-to-revolutionize-autism-and-adhd-diagnosis?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ABVC","ADHD","BK4139"],"gpt_icon":0},{"id":"2483062772","title":"BlinkLab teams up with Monash to trial tech in autism, ADHD study","url":"https://stock-news.laohu8.com/highlight/detail?id=2483062772","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483062772?lang=en_us&edition=fundamental","pubTime":"2024-11-13 07:07","pubTimestamp":1731452820,"startTime":"0","endTime":"0","summary":"BlinkLab  has confirimed its involvement in a Monash Uni-based study examining its tech’s ability to diagnose autism and ADHD.BlinkLab offers software that analyses a child’s eye movements informed by research suggesting those with autism and ADHD display unique eye behaviours not witnessed in people without those conditions.BlinkLab now finds itself on a data-finding mission within the larger Monash MAGNET large cohort study which is trying to enrol 1,000 families with children diagnosed with either or both conditions. The uni’s Turner Institute is ultimately overseeing the program.“Using BlinkLab Dx 1, we aim to complete comprehensive deep sensory phenotyping of subjects with only autism, only ADHD, or with both autism and ADHD from the large MAGNET cohort,” the company wrote on Wednesday.BlinkLab – and heads at Turner and Monash – are trying to figure out if the company’s software can outperform other traditional diagnosis methods.Join the discussion: See what HotCopper users are sa","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://themarketonline.com.au/blinklab-teams-up-with-monash-to-trial-tech-in-autism-adhd-study-2024-11-13/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BB1.AU","ABVC","BK4139","BK7094","ADHD"],"gpt_icon":0},{"id":"2483105732","title":"Press Release: Alto Neuroscience Reports Third Quarter 2024 Financial Results and Recent Business Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2483105732","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483105732?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:10","pubTimestamp":1731445800,"startTime":"0","endTime":"0","summary":"-- Topline data from two MDD trials expected in the first half of 2025: Phase 2b trial of ALTO-300 as an adjunctive treatment and Phase 2a trial of ALTO-203 in patients with anhedonia --. -- Additional Phase 2 studies ongoing: ALTO-101 in schizophrenia and ALTO-100 as an adjunctive treatment in bipolar depression --. -- Key learnings from ALTO-100 Phase 2b MDD trial including clinically meaningful effect observed in a pre-specified secondary analysis and evidence of stratification using the pre-specified enrichment biomarker in patients with confirmed drug compliance --. -- Strong cash position of approximately $182 million is expected to fund planned operations into 2027, and through at least four additional clinical study readouts --. Alto Neuroscience, Inc.   a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the third quarter ended September 30, 2024, and highlighted","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","ABVC","GRO","ANRO","CIAS"],"gpt_icon":0},{"id":"2483052981","title":"Xenon Reports Q3 2024 Financial Results and Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2483052981","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483052981?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:01","pubTimestamp":1731445260,"startTime":"0","endTime":"0","summary":"– Phase 3 epilepsy program advancing with X-TOLE2 topline FOS data anticipated in H2 2025 – Long-term azetukalner results from X-TOLE open-label extension study in FOS to be presented at AES – Phase 3","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2979642/33485/en/Xenon-Reports-Q3-2024-Financial-Results-and-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","LU0266512127.USD","LU0300736062.USD","IE00BSNM7G36.USD","ABVC","BK4588","LU0122376428.USD","LU0456854461.SGD","LU0788109394.HKD","LU0170899867.USD","LU0300736492.USD","MPC","BK4138","LU0368265418.SGD","BK4585","DBP"],"gpt_icon":0},{"id":"2482703068","title":"Neuronetics Reports Record Third Quarter 2024 Financial and Operating Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2482703068","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482703068?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:10","pubTimestamp":1731413400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Nov.  12, 2024  (GLOBE NEWSWIRE) -- Neuronetics,Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology company with a strategic vision of transforming","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/12/2978940/0/en/Neuronetics-Reports-Record-Third-Quarter-2024-Financial-and-Operating-Results.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4082","BK4139","ABVC","STIM","WRD"],"gpt_icon":0},{"id":"2482570815","title":"Press Release: Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482570815","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482570815?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025. Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer's disease agitation with data expected in second half of 2025. Clinical study for next M4 PAM program expected to commence clinical in the first half of 2025. Strong financial position with $341.3 million in cash, cash equivalents and marketable securities now expected to support operations into mid-2026. Navacaprant  is a highly selective, novel, once-daily kappa opioid receptor  antagonist being developed as a potential monotherapy treatment for MD","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","LENZ","BK4017","KOR","NMRA","ABVC","BK4563","PAM","BK4081","BK4139"],"gpt_icon":0},{"id":"2482089997","title":"Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2482089997","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482089997?lang=en_us&edition=fundamental","pubTime":"2024-11-12 20:00","pubTimestamp":1731412800,"startTime":"0","endTime":"0","summary":"Total 3Q 2024 net product revenue of $104.8 million, representing 81% year-over-year growth. Auvelity 3Q 2024 net product sales of $80.4 million, representing 113% year-over-year growth. Sunosi 3Q 2024 net product revenue of $24.4 million representing 21% year-over-year growth. Second expansion of Auvelity psychiatry sales force planned for 1Q 2025. NDA resubmission for AXS-07 for the treatment of migraine accepted by the FDA with PDUFA goal date of January 31, 2025. Topline results of ADVANCE-2 and ACCORD-2 Phase 3 trials of AXS-05 in Alzheimer’s disease agitation on track for 4Q 2024. Topline results of ENCORE Phase 3 trial of AXS-12 in narcolepsy on track for 4Q 2024. Topline results of FOCUS Phase 3 trial of solriamfetol in ADHD anticipated 1Q 2025. Total net product revenue for the third quarter of 2024 was $104.8 million, representing 81% year-over-year growth. Total net product revenue for the comparable period in 2023 was $57.8 million.Auvelity net product sales were $80.4 mill","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/RW9dIS08rGlshoyfw2yAIA--~B/aD0xMjU7dz0yMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/RW9dIS08rGlshoyfw2yAIA--~B/aD0xMjU7dz0yMjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/312dca55eae60554184e623918f0f20a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/axsome-therapeutics-reports-third-quarter-120000482.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["AXSM","ADHD","WRD","BK4007","BK4585","BK4135","BK4139","BK4505","CNS","ABVC"],"gpt_icon":0},{"id":"2482859780","title":"CING: Third Quarter Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2482859780","media":"Zacks Small Cap Research","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482859780?lang=en_us&edition=fundamental","pubTime":"2024-11-12 16:15","pubTimestamp":1731399300,"startTime":"0","endTime":"0","summary":"Cingulate, Inc.  reported third quarter results on November 7th, 2024. No revenues were reported and operating expense of $3.3 million was recognized. During the third quarter and to date the company was issued a European patent for tripulse stimulant formulations, participated in multiple business media interviews and started its final study for CTx-1301 required for the new drug application . The NDA is expected to be submitted in mid-2025. Cingulate was also able to raise additional capital through its At-the-Market  facility and other arrangements, increasing its end of quarter cash balance to over $10 million.Cingulate reported third quarter 2024 results in a press release and Form 10-Q filing with the SEC on November 7th. For the quarter ending September 30, 2024 operating expenses of $3.3 million were recognized. Net loss for 3Q:24 totaled  million or  per share. For the third quarter of 2024 versus the same prior year period:","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cing-third-quarter-results-081500584.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ABVC","CING","CINGW","BK4007","BK4139"],"gpt_icon":0},{"id":"2482775425","title":"I'm a college professor, and I'm not sure I'll send my kid to college. A degree isn't required for success.","url":"https://stock-news.laohu8.com/highlight/detail?id=2482775425","media":"businessinsider.com","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482775425?lang=en_us&edition=fundamental","pubTime":"2024-11-12 01:12","pubTimestamp":1731345160,"startTime":"0","endTime":"0","summary":"\" The student answered with a line that seemed ripped from the parenting playbook: \"Well, you have to go to college to get a well-paying career, right?\"While it's statistically true that those with college degrees tend to make more than those without, statistics don't tell the whole story. The trouble was this student had no idea what career she wanted, so she couldn't have known whether college mattered for her.I don't fully subscribe to the idea that we should only educate students for their desired careers. College is about more than that, including teaching valuable critical thinking skills that help us be better employees, citizens, and people.But we also ca","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.businessinsider.com/professor-not-send-son-college-2024-11","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"businsider_highlight","symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2482786098","title":"Nexalin Technology CEO Provides Letter to Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2482786098","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482786098?lang=en_us&edition=fundamental","pubTime":"2024-11-11 21:00","pubTimestamp":1731330000,"startTime":"0","endTime":"0","summary":"HOUSTON, TX, Nov.  11, 2024  (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) (the “Company” or “Nexalin”) today released a letter to shareholders from its CEO Mark White: Dear Shareh","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/11/11/2978270/0/en/Nexalin-Technology-CEO-Provides-Letter-to-Shareholders.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2482480415","title":"The New Must-Have for Overwhelmed Kids: An Executive Function Coach -- WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=2482480415","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482480415?lang=en_us&edition=fundamental","pubTime":"2024-11-09 01:30","pubTimestamp":1731087000,"startTime":"0","endTime":"0","summary":"By Jenny Anderson | Illustrations by Vincent Kilbride. Soon after her son started middle school, Kay Nash, head of talent at a Washington, D.C., law firm, started worrying about his organizational skills and study habits. He'd been diagnosed with ADHD and anxiety in third grade. A combination of medication and school support had helped him navigate elementary school, but he still struggled. Suddenly, she saw more work in more subjects, more projects and more homework coming down the pike.\"I didn't want to be micromanaging schoolwork, yelling about deadlines and yelling about how important it is to get good grades,\" Nash recalls. \"I wanted a positive and encouraging relationship with my child.\". She wanted to find someone to help him get organized and, more important, to teach him the life skills needed to organize himself for the future. Nash found what she was looking for in the growing new field of executive function, or EF, coaches.Developing executive function skills has long been ","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","ABVC"],"gpt_icon":0},{"id":"2481904136","title":"Intra-Cellular Therapies Announces Presentations at the 2024 Psych Congress and NEI Congress","url":"https://stock-news.laohu8.com/highlight/detail?id=2481904136","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481904136?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:00","pubTimestamp":1730984400,"startTime":"0","endTime":"0","summary":"Presentations include results from two pivotal studies  evaluating lumateperone as an adjunctive therapy to antidepressants for the treatment of major depressive disorder . Results show robust efficacy and favorable safety and tolerability profile for CAPLYTA. In the adjunctive MDD setting these data present a compelling clinical profile for lumateperone in the treatment of MDD. These results further support the Company’s vision for CAPLYTA to become a leading option for patients and providers across mood disorders.About Major Depressive DisorderMajor Depressive Disorder  is a common mood disorder in the U.S. affecting an estimated 21 million adults each year. Depressive disorders are the number two cause of years lived with disability in the world. Symptoms include sadness, hopelessness, helplessness, feelings of guilt, irritability, loss of interest in formerly pleasurable activities, cognitive i","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/s3sKX_TYeP36lRz0OyReEw--~B/aD02NDg7dz02NDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d313c5e820d48076ad3705521a8a9b66","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/s3sKX_TYeP36lRz0OyReEw--~B/aD02NDg7dz02NDg7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/d313c5e820d48076ad3705521a8a9b66"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/intra-cellular-therapies-announces-presentations-130000256.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["NMS","CNS","ABVC","ITCI","LU0889565916.HKD","BK4135","BK4007","BK4139","LU0320765992.SGD","LU0109394709.USD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.abvcpharma.com","stockEarnings":[{"period":"1week","weight":-0.0503},{"period":"1month","weight":-0.1044},{"period":"3month","weight":-0.2417},{"period":"6month","weight":-0.5327},{"period":"1year","weight":-0.6855},{"period":"ytd","weight":-0.569}],"compareEarnings":[{"period":"1week","weight":-0.0208},{"period":"1month","weight":0.0059},{"period":"3month","weight":0.0567},{"period":"6month","weight":0.1063},{"period":"1year","weight":0.301},{"period":"ytd","weight":0.2324}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. is a subsidiary of YuanGene Corporation.","yearOnYearQuotes":[{"month":1,"riseRate":0.333333,"avgChangeRate":-0.067297},{"month":2,"riseRate":0,"avgChangeRate":-0.074163},{"month":3,"riseRate":0.666667,"avgChangeRate":0.008224},{"month":4,"riseRate":0.333333,"avgChangeRate":0.005269},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.062733},{"month":6,"riseRate":0.166667,"avgChangeRate":1.432014},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.126621},{"month":8,"riseRate":0.428571,"avgChangeRate":-0.087867},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.085669},{"month":10,"riseRate":0.428571,"avgChangeRate":-0.065345},{"month":11,"riseRate":0.714286,"avgChangeRate":0.057198},{"month":12,"riseRate":0.5,"avgChangeRate":0.000542}],"exchange":"NASDAQ","name":"ABVC BioPharma, Inc.","nameEN":"ABVC BioPharma, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ABVC BioPharma, Inc.,ABVC,ABVC BioPharma, Inc.股票,ABVC BioPharma, Inc.股票老虎,ABVC BioPharma, Inc.股票老虎国际,ABVC BioPharma, Inc.行情,ABVC BioPharma, Inc.股票行情,ABVC BioPharma, Inc.股价,ABVC BioPharma, Inc.股市,ABVC BioPharma, Inc.股票价格,ABVC BioPharma, Inc.股票交易,ABVC BioPharma, Inc.股票购买,ABVC BioPharma, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ABVC BioPharma, Inc.(ABVC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ABVC BioPharma, Inc.(ABVC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}